Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CME Group Inc. (CME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a publicly traded operator in the securities and commodity exchanges industry. CME Group files a range of documents with the U.S. Securities and Exchange Commission, including current reports on Form 8-K that provide updates on financial results, corporate events and governance matters.
Recent Form 8-K filings illustrate how CME Group uses SEC reports to communicate with investors. One 8-K describes the release of quarterly financial results, including the use of non-GAAP measures such as non-GAAP revenues, expenses, operating income, net income and earnings per share, together with reconciliations to the most comparable GAAP figures. Another 8-K reports a jury verdict in favor of CME Group and the Board of Trade of the City of Chicago, Inc. in a class action involving certain Class B shareholders and members. A further 8-K discloses the planned retirement of the company’s Chief Accounting Officer and outlines the transition process.
In addition to 8-Ks, CME Group’s SEC reporting framework includes annual and quarterly reports, proxy statements and other filings that address topics such as results of operations, financial condition, risk factors, corporate governance and compensation. These documents help investors understand the company’s role as a derivatives marketplace offering futures, options, cash and OTC trading across interest rates, equity indexes, foreign exchange, energy, agricultural products, metals and cryptocurrencies, as well as its operation of CME Clearing and electronic platforms like CME Globex, BrokerTec and EBS.
On Stock Titan, CME filings are supplemented with AI-powered summaries designed to explain the key points of lengthy documents, such as 10-K and 10-Q reports, in accessible language. Users can quickly identify major themes, while still having access to the full text of each filing. The page also provides visibility into event-driven filings like Form 8-K, which can include announcements about earnings releases, legal outcomes, executive changes and other material developments.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting a proposed sale of 1,000 common shares tied to CME with an aggregate value listed as
The filing also lists restricted stock lots of 748 shares with grant date
CME Group Inc: The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting 36,248,559 shares beneficially owned, representing 10.10% of common stock. The filing states shared voting power 3,697,661 and shared dispositive power 36,248,559. It notes an internal realignment effective
CME Group Inc. files its annual report outlining a broad derivatives, clearing, cash markets and data business built around global benchmark futures and options, cash U.S. Treasuries, FX and market data services. The company emphasizes deep liquidity, risk management and capital efficiency for a diverse institutional customer base.
In 2025, futures and options average daily volume reached 28.1 million contracts, with strong growth in interest rates, agricultural, energy and metals products and micro contracts. Cash markets via BrokerTec and EBS generated
CME highlights strategic initiatives in product expansion, global distribution, OTC alternatives, crypto, environmental products and a major multi‑year migration of core systems to Google Cloud. It is launching a new securities clearing subsidiary to support upcoming SEC U.S. Treasury and repo clearing mandates and continues to grow licensing and benchmark businesses such as CME Term SOFR. The report also details extensive regulatory oversight, key risk factors and human capital metrics, including roughly 3,875 employees worldwide and strong engagement scores.
CME Group Inc. director Bryan T. Durkin reported an open-market sale of Class A common stock. On February 23, 2026, he sold 4,200 shares at a weighted average price of
CME Group submitted a Form 144 reporting a proposed sale of common shares. The notice lists a broker, Morgan Stanley Smith Barney LLC, and an intended sale date of
CME Group Inc. director Martin J. Gepsman reported an open-market sale of Class A common stock. He sold 300 shares at a price of
CME Group Inc. director Dennis Suskind reported selling 748 shares of Class A common stock on February 6, 2026 at a price of $300 per share. After this transaction, he beneficially owned 2,699 shares of CME Group common stock in direct ownership.
CME Group has a holder filing a notice under Rule 144 to sell up to 748 shares of Class A common stock through J.P. Morgan Securities on the NASDAQ around 02/06/2026. Shares outstanding were 360,596,647, indicating this is a very small potential sale relative to the total.
CME Group Inc. filed a current report to furnish its earnings press release for the quarter and year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and outlines the company’s financial results.
The release includes several non-GAAP financial measures, such as adjusted revenues, expenses, operating income, net income and earnings per share. Management states these are intended to supplement GAAP results and improve comparability with prior periods, and provides reconciliations to the most directly comparable GAAP figures in accordance with Regulation G.